

## A new peer-reviewed article on TK 210 ELISA was released today

**An article has been published in the PLOS One journal, where the study demonstrates the robustness and simplicity of the AroCell TK 210 ELISA assay compared to TK activity assays.**

The article entitled "*Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples*", by Kiran Jagarlamudi et al., briefly describes the antibody selection and different phases in AroCell TK 210 ELISA assay development and assess in detail the analytical performance of the TK 210 ELISA to demonstrate the robustness and simplicity of the assay compared to TK activity assays.

The evaluation of the clinical performance showed that the AroCell TK 210 ELISA has a higher sensitivity for TK1 in serum from subjects with solid tumors and a similar sensitivity as TK1 activity for hematological malignancies. This suggests that the AroCell TK 210 ELISA facilitate the application of TK1 as a biomarker for solid tumors and also broadens the clinical applications of TK1 in cancer management.

The article can be read here:

<https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0275444>

### Contacts

---

Anders Hultman, CEO  
Phone: +46(0)18 50 30 20  
E-mail: [anders.hultman@arocell.com](mailto:anders.hultman@arocell.com)

### About TK 210 ELISA

---

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

## About AroCell

---

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; [www.arocell.com](http://www.arocell.com)

## Attachments

---

[A new peer-reviewed article on TK 210 ELISA was released today](#)